Wouter Haazen

908 total citations
28 papers, 660 citations indexed

About

Wouter Haazen is a scholar working on Epidemiology, Infectious Diseases and Endocrinology. According to data from OpenAlex, Wouter Haazen has authored 28 papers receiving a total of 660 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Epidemiology, 10 papers in Infectious Diseases and 6 papers in Endocrinology. Recurrent topics in Wouter Haazen's work include Escherichia coli research studies (6 papers), Respiratory viral infections research (5 papers) and Viral gastroenteritis research and epidemiology (4 papers). Wouter Haazen is often cited by papers focused on Escherichia coli research studies (6 papers), Respiratory viral infections research (5 papers) and Viral gastroenteritis research and epidemiology (4 papers). Wouter Haazen collaborates with scholars based in United States, Belgium and Netherlands. Wouter Haazen's co-authors include Marina De Smet, Benjamin Lang, Viktoria Moschetti, Stephan Glund, Stephen H. Norris, Paul Reilly, Joachim Stangier, Neliëtte van Niekerk, Dietmar Ganßer and Benoît Callendret and has published in prestigious journals such as Blood, Journal of the American College of Cardiology and The Journal of Infectious Diseases.

In The Last Decade

Wouter Haazen

28 papers receiving 634 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wouter Haazen United States	14	242	234	137	75	74	28	660
Fernando Ballester Laguna Spain	17	421 1.7×	228 1.0×	83 0.6×	24 0.3×	7 0.1×	45	973
R Thorpe	2	131 0.5×	75 0.3×	37 0.3×	17 0.2×	36 0.5×	4	389
David M. Tehrani United States	13	235 1.0×	217 0.9×	222 1.6×	23 0.3×	14 0.2×	38	1.2k
Young Jin Hong South Korea	14	233 1.0×	150 0.6×	57 0.4×	5 0.1×	134 1.8×	60	609
George Perez United States	15	353 1.5×	413 1.8×	32 0.2×	2 0.0×	49 0.7×	36	785
Daniel Bernstein United States	9	118 0.5×	86 0.4×	31 0.2×	60 0.8×	9 0.1×	15	477
Christina Jorup-Rönström Sweden	12	191 0.8×	425 1.8×	8 0.1×	6 0.1×	46 0.6×	23	691
Beth A. Dy United States	14	80 0.3×	92 0.4×	13 0.1×	13 0.2×	7 0.1×	20	1.1k
Thanh Lecompte Switzerland	9	285 1.2×	238 1.0×	35 0.3×	47 0.6×	7 0.1×	15	470
A Terragna Italy	15	318 1.3×	177 0.8×	10 0.1×	9 0.1×	17 0.2×	46	676

Countries citing papers authored by Wouter Haazen

Since Specialization

Citations

This map shows the geographic impact of Wouter Haazen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wouter Haazen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wouter Haazen more than expected).

Fields of papers citing papers by Wouter Haazen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wouter Haazen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wouter Haazen. The network helps show where Wouter Haazen may publish in the future.

Co-authorship network of co-authors of Wouter Haazen

This figure shows the co-authorship network connecting the top 25 collaborators of Wouter Haazen. A scholar is included among the top collaborators of Wouter Haazen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wouter Haazen. Wouter Haazen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Langley, Joanne M., Terry Nolan, Mika Rämet, et al.. (2024). A Phase 1/2a Study Evaluating Safety and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers Aged 12–24 Months. Open Forum Infectious Diseases. 11(9). ofae453–ofae453. 2 indexed citations

Fierro, Carlos, Michal Sarnecki, Bart Spiessens, et al.. (2024). A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTI. npj Vaccines. 9(1). 106–106. 8 indexed citations

Fierro, Carlos, Michal Sarnecki, Bart Spiessens, et al.. (2023). IMMUNOGENICITY OUTCOMES OF A RANDOMIZED, MULTICENTER, INTERVENTIONAL, FIRST-IN-HUMAN, PHASE 1/2A STUDY OF VAC52416 (EXPEC10V), A VACCINE CANDIDATE FOR THE PREVENTION OF INVASIVE ESCHERICHIA COLI DISEASE. International Journal of Infectious Diseases. 130. S114–S114. 1 indexed citations

Fierro, Carlos, Michal Sarnecki, Bart Spiessens, et al.. (2023). Safety, Reactogenicity, Immunogenicity, and Dose Selection of 10-Valent Extraintestinal Pathogenic Escherichia coli Bioconjugate Vaccine (VAC52416) in Adults Aged 60–85 Years in a Randomized, Multicenter, Interventional, First-in-Human, Phase 1/2a Study. Open Forum Infectious Diseases. 10(8). ofad417–ofad417. 17 indexed citations

Stuart, Arabella, Miia Virta, Kristi L. Williams, et al.. (2022). Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18–50 Years and RSV-Seropositive Children 12–24 Months. The Journal of Infectious Diseases. 227(1). 71–82. 28 indexed citations

Rosenberg, Steven, Marc J. M. Bonten, Wouter Haazen, et al.. (2020). Epidemiology and O-Serotypes of Extraintestinal Pathogenic Escherichia coli Disease in Patients Undergoing Transrectal Ultrasound Prostate Biopsy: A Prospective Multicenter Study. The Journal of Urology. 205(3). 826–832. 7 indexed citations

Sadoff, Jerald, Els De Paepe, Wouter Haazen, et al.. (2020). Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults. The Journal of Infectious Diseases. 223(4). 699–708. 42 indexed citations

Frenck, Robert W., John Ervin, Laurence Chu, et al.. (2019). Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial. The Lancet Infectious Diseases. 19(6). 631–640. 57 indexed citations

Norris, Stephen H., Steven Ramael, Ippei Ikushima, et al.. (2017). Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies. British Journal of Clinical Pharmacology. 83(8). 1815–1825. 9 indexed citations

10.

Leroux‐Roels, Geert, Pierre Van Damme, Wouter Haazen, et al.. (2016). Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults. Vaccine. 34(27). 3156–3163. 27 indexed citations

11.

Glund, Stephan, Joachim Stangier, Joanne van Ryn, et al.. (2016). Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study. Clinical Pharmacokinetics. 56(1). 41–54. 58 indexed citations

12.

Krishna, Rajesh, Carol Addy, Daniel Tatosian, et al.. (2016). Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once‐Weekly Dipeptidyl Peptidase‐4 (DPP‐4) Inhibitor, After Single and Multiple Doses in Healthy Subjects. The Journal of Clinical Pharmacology. 56(12). 1528–1537. 29 indexed citations

13.

Vanhoutte, Frédéric, Sonia Dupont, Roland Blanqué, et al.. (2015). P612. Human safety, pharmacokinetics and pharmacodynamics of the GPR84 antagonist GLPG1205, a potential new approach to treat IBD.. Journal of Crohn s and Colitis. 9(suppl 1). S387–S387. 3 indexed citations

14.

Nel, Annaléne, et al.. (2014). Drug-drug Interactions between the Dapivirine Vaginal Ring (Ring-004) and Miconazole Nitrate Vaginal Capsule (Gyno-Daktarin ^® ). AIDS Research and Human Retroviruses. 30(S1). A144–A144. 8 indexed citations

15.

Nel, Annaléne, Wouter Haazen, Jeremy Nuttall, et al.. (2014). A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women. AIDS. 28(10). 1479–1487. 60 indexed citations

16.

Glund, Stephan, Joachim Stangier, Michael Schmohl, et al.. (2014). Idarucizumab, a Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Elderly and Renally Impaired Subjects. Blood. 124(21). 344–344. 59 indexed citations

17.

Vanhoutte, Frédéric, Sonia Dupont, Wouter Haazen, et al.. (2014). DOP070 The FFA2 antagonist GLPG0974: opportunity to treat neutrophil-driven inflammation. Journal of Crohn s and Colitis. 8. S48–S48. 1 indexed citations

18.

Haazen, Wouter, et al.. (2010). 2012 VIROLOGICAL RESPONSE, SAFETY, AND PHARMACOKINETIC PROFILE FOLLOWING SINGLE- AND MULTIPLE-DOSE ADMINISTRATION OF ACH-0141625 PROTEASE INHIBITOR TO HEALTHY VOLUNTEERS AND HCV GENOTYPE-1 PATIENTS. Journal of Hepatology. 52. S468–S468. 8 indexed citations

19.

Béliard, R, Tony Waegemans, Christophe de Romeuf, et al.. (2008). A human anti‐D monoclonal antibody selected for enhanced FcγRIII engagement clears RhD⁺ autologous red cells in human volunteers as efficiently as polyclonal anti‐D antibodies. British Journal of Haematology. 141(1). 109–119. 30 indexed citations

20.

Mistry, Goutam C., Arthur Bergman, Wen‐Lin Luo, et al.. (2007). Multiple‐Dose Administration of Sitagliptin, a Dipeptidyl Peptidase‐4 Inhibitor, Does Not Alter the Single‐Dose Pharmacokinetics of Rosiglitazone in Healthy Subjects. The Journal of Clinical Pharmacology. 47(2). 159–164. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact